SAXENDA

Peak

liraglutide

NDASUBCUTANEOUSSOLUTION
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Glucagon-like Peptide-1 (GLP-1) Agonists

Pharmacologic Class:

GLP-1 Receptor Agonist

Clinical Trials (5)

NCT07225816Phase 1Recruiting

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Started Nov 2025
75 enrolled
Obesity
NCT06283641N/ACompleted

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.

Started Apr 2024
300 enrolled
Obesity
NCT05438186N/AWithdrawn

INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records

Started Sep 2022
0
Obesity
NCT05479591N/AWithdrawn

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

Started Jul 2022
0
Diabetes Mellitus, Type 2
NCT04763564Phase 2Terminated

Efficacy of Liraglutide Therapy in Patients With IPAA

Started Mar 2022
8 enrolled
PouchitisIrritable Pouch Syndrome

Loss of Exclusivity

LOE Date
Jul 9, 2037
138 months away
Patent Expiry
Jul 9, 2037

Patent Records (4)

Patent #ExpiryTypeUse Code
8114833
Aug 13, 2025Expired
Product
8114833*PED
Feb 13, 2026Expired
9968659
Jan 9, 2037
U-2438
9968659*PED
Jul 9, 2037